Atopic dermatitis (AD) is a chronic disease that affects an increasing number of children and adults. The skin is dry and ...

Sitryx advances development of PKM2 modulator SYX-5219 into atopic dermatitis patients following clinical evidence of immunomodulatory activity ...

Sanofi has announced that its amlitelimab has shown positive results in the treatment of patients 12 years and older with ...

Shares of Corvus Pharmaceuticals rose after its investigational drug soquelitinib showed positive results in an early-stage trial in atopic dermatitis patients. The stock surged 50% to $12.10 in ...

Corvus Pharmaceuticals (NASDAQ:CRVS) shares surged 48% on Tuesday after the company released positive findings from a Phase 1 ...

Experts discuss the importance of balancing effective symptom control with quality of life in managing chronic pediatric atopic dermatitis, emphasizing personalized treatment plans that address both ...

Experts discuss the unique challenges of managing atopic dermatitis (AD) in pediatric and adolescent patients, emphasizing the strategic use of topical treatments to improve adherence, reduce ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab is approved for atopic dermatitis in children aged 6 months and older. Patients on dupilumab did not ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

If you’re a person of color, finding the right treatment for atopic dermatitis, a common form of eczema, can be challenging. Even though the disease is more prevalent in Black Americans than white ...